The European Commission authorised the conversion of the conditional marketing authorisation for Jcovden to standard marketing authorisation Spikevax (previously COVID-19 Vaccine Moderna)ĮMA published assessment reports following its review of the risk of heavy menstrual bleeding with Comirnaty and SpikevaxĮMA published clinical data supporting the addition of a new strength of Comirnaty for use in children aged 6 months to 4 yearsĮMA published updated product information for Veklury, with an increase in its approved shelf lifeĮMA's CHMP recommended converting the conditional marketing authorisation for Paxlovid to standard marketing authorisationĮMA published clinical data supporting the use of COVID-19 Vaccine Valneva in adults aged 18 to 50ĮMA published updated product information for COVID-19 treatment Paxlovid, with an increase in its approved shelf life The video recording is available of EMA's latest COVID-19 and other public health emergencies press briefingĮMA is holding a regular press briefing on COVID-19 and other public health emergencies on Wednesday 15 February 2023ĮMA published the assessment report for Spikevax supporting the extension of indication for use of its adapted BA.1 version as a booster in children aged 6 to 11 The European Commission authorised Bimervax (previously COVID-19 Vaccine HIPRA)ĮMA's CHMP recommended authorising Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and olderĮMA recommends approval of Bimervax as a COVID-19 booster vaccineĮMA's CHMP started evaluating the marketing authorisation application for Bimervax (previously COVID-19 Vaccine HIPRA)ĮMA published clinical data for Spikevax supporting the use of its adapted BA.1 version as a booster in children aged 6 to 11ĮMA's CHMP recommended authorising COVID-19 Vaccine Valneva as a booster in adults aged 18 to 50ĬOVID-19 Vaccine (inactivated, adjuvanted) ValnevaĮMA published clinical data supporting the use of Vaxzevria as a booster doseĮMA's CHMP approved a new manufacturing site for the active substance of NuvaxovidĮMA published updated information for COVID-19 Vaccine Valneva, with an increase in its approved shelf life Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023ĮMA's CHMP recommended an extension of indication for Ronapreve to include people aged 12 and older with a negative antibody test who are receiving Oxygen The video recording is available of EMA's last regular COVID-19 and other public health emergencies press briefingĮMA regular press briefing on public health emergenciesĮMA is holding its last regular press briefing on COVID-19 and other public health emergencies on Tuesday 6 June 2023ĮMA's CHMP recommended converting the conditional marketing for Nuvaxovid to standard marketing authorisationĮMA's CHMP recommended extending the shelf life of Nuvaxovid from 9 to 12 monthsĮMA published clinical data for COVID-19 Vaccine Valneva supporting its use as a booster in adults aged 18 to 50ĮMA published clinical data for Evusheld supporting its use to treat COVID-19 in adults and adolescentsĮMA published clinical data for Evusheld supporting its use to prevent COVID-19 in adults and adolescentsĮMA published clinical data for VidPrevtyn Beta supporting its use as a vaccine in adultsĮMA's CHMP recomended an extension of indication for Spikevax to include use of its adapted BA.4-5 version as a booster in children aged 6 to 11
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |